Cidara Therapeutics soared 250% after strong Phase 2b NAVIGATE trial results for CD388, a novel antiviral for flu prophylaxis. CD388 demonstrated up to 76% efficacy, outperforming many traditional flu ...
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...
Standard treatment for breathing problems caused by obstructive sleep apnea is a medical device. But many people find it uncomfortable to wear the mask that comes with a continuous positive airway ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures ...
Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Disc. 23, 656–657; 2024). With the ...
A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication. But the Swiss biotech saw promise in other ...
GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive ...
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).
What Happened: The New York-based clinical-stage biopharmaceutical company received final meeting minutes from the U.S. Food and Drug Administration confirming alignment on a registrational path for ...
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. The Japanese pharma had been evaluating the alpha-synuclein antibody, called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback